FDA
-
-
-
-
-
-
-
Opthea Reports Positive Three-Month Data from Phase 1b Dose Escalation Study for OPT-302 in Diabetic Macular Edema
-
-
-
-
-
-
-
Opthea’s Phase 2b Wet AMD Clinical Trial Reaches Mid-Way Point of Patient Recruitment
-
-
-
-
-
-
-
Opthea Receives Notice of Allowance for Key Patent Covering OPT-302 in the United States
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

